View in EDS

Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer.

Saved in:
Bibliographic Details
Title: Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer.
Authors: Cursano G; Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Concardi A; Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Ivanova M; Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy., Frascarelli C; Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Mane E; Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy., Mangione E; Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Santaguida S; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy., Tosoni D; Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy., Pece S; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy., Marra A; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy., Criscitiello C; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy., Curigliano G; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy., Viale G; Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Venetis K; Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy. Konstantinos.venetis@ieo.it., Rocco EG; Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Fusco N; Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Source: Molecular diagnosis & therapy [Mol Diagn Ther] 2025 Nov; Vol. 29 (6), pp. 849-857. Date of Electronic Publication: 2025 Sep 06.
Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 101264260 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-2000 (Electronic) Linking ISSN: 11771062 NLM ISO Abbreviation: Mol Diagn Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1179-2000
DOI:10.1007/s40291-025-00814-5